ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Albany Molecular Research Inc. (AMRI) has made a series of investments in R&D services for therapies targeting orphan and rare diseases. The drug services firm has added batch manufacturing suites with capacity for 10–15 kg at its headquarters facility in Albany, New York. In Grafton, Wisconsin, AMRI has expanded its hydrogenation, analytical, filtering and drying, and spectrometry capabilities. The company added an unspecified number of researchers at these sites as well as at its formulation development and sterile drug manufacturing operation in Glasgow, Scotland.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter